Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Short-term Investments (2019 - 2025)

Nurix Therapeutics (NRIX) has disclosed Short-term Investments for 7 consecutive years, with $346.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Short-term Investments fell 30.75% to $346.0 million in Q4 2025 year-over-year; TTM through Nov 2025 was $346.0 million, a 30.75% decrease, with the full-year FY2025 number at $346.0 million, down 30.75% from a year prior.
  • Short-term Investments was $346.0 million for Q4 2025 at Nurix Therapeutics, down from $350.4 million in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $499.6 million in Q4 2024 to a low of $176.7 million in Q1 2021.
  • A 5-year average of $281.2 million and a median of $244.1 million in 2022 define the central range for Short-term Investments.
  • Biggest YoY gain for Short-term Investments was 143.98% in 2025; the steepest drop was 30.75% in 2025.
  • Nurix Therapeutics' Short-term Investments stood at $215.2 million in 2021, then rose by 13.69% to $244.7 million in 2022, then fell by 4.65% to $233.3 million in 2023, then skyrocketed by 114.16% to $499.6 million in 2024, then tumbled by 30.75% to $346.0 million in 2025.
  • Per Business Quant, the three most recent readings for NRIX's Short-term Investments are $346.0 million (Q4 2025), $350.4 million (Q3 2025), and $401.5 million (Q2 2025).